Access investment deals from longevity innovators

A holding company model for Longevity

A new class of medicine

Interested in SPVs?

Investment briefing

Edging ahead in Q2 but still held back:
Q2 2023: longevity investment report
Read now
Investment review for January to March 2023. “If you’re going through hell, keep going.” Winston Churchill:
Q1 2023: longevity investment report
Read now
Full year 2022 report on the state of longevity investment: the numbers, the sectors, the top deals, the key players and the outlook for 2023:
Annual Longevity Investment Report
Read now
Disease management to disease modification – removing plaque to undo atherosclerosis:
Atherosclerosis
Read now
Delaying the menopause to increase women’s healthspan:
Reproductive longevity
Read now
Leading a new era of personalised, preventative health and optimal aging:
Longevity diagnostics
Read now
Supplementing your Longevity supplement knowledge:
Longevity supplements
Read now
Managing senescent cells to drive human longevity:
Senotherapeutics
Read now

News

Laverock lands £13.5m to advance gene silencing technology

British gene-silencing technology company Laverock Therapeutics has secured £13.5 million in a…

US government backs thymus rejuvenation project with $37m ARPA-H funding

Project led by Thymmune Therapeutics aims to restore damaged or non-functional thymus…

Novo Nordisk Foundation’s new €127m cell therapy facility targets chronic disease

Denmark’s Novo Nordisk Foundation has committed up to €127 million to establish…

Investors from around the world gather in Gstaad

Longevity.Technology’s CEO reports from Day 1 of the Longevity Investors Conference in…

Company alerts

  • June 2, 2023
    Stealth BioTherapeutics
    Stealth BioTherapeutics (NAS: MITO)
    LT 2419
    419 of 880
    Stealth BioTherapeutics is a biopharmaceutical company dedicated to developing therapies addressing mitochondrial dysfunction in genetic mitochondrial diseases and age-related conditions. Their lead candidate, elamipretide, penetrates cell membranes and targets the inner mitochondrial membrane, enhancing mitochondrial respiration and function. This elamipretide-cardiolipin interaction improves mitochondrial structure and is being investigated for ophthalmic, neuromuscular, and cardiomyopathy disorders. Their second-generation candidate, SBT-272, targets neurological diseases like amyotrophic lateral sclerosis. Collaborating with patients and advocacy groups, Stealth aims to address unmet needs and raise awareness about mitochondrial disease.
    Longevity pillar
    • Treatment
    • Prevention
    Longevity domain:
    • Longevity drugs
    • Neuropharma
    • Discovery platforms
    Longevity target: Aging Driver, Aging Disease
    and Pharmanovia partner for commercialisation of elamipretide. Read more
  • June 2, 2023
    Adiso Therapeutics
    ADISO therapeutics
    LT 2012
    12 of 880
    ADISO therapeutics creates novel therapies for inflammatory diseases. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns. To tackle these challenges, ADISO therapeutics are advancing an innovative pipeline of multi-modal small molecules. ADS051, a pioneering oral, gut-restricted modulator, targets ulcerative colitis. Likewise, ADS032, a first-in-class small molecule, inhibits both NLRP3 & NLRP1 inflammasomes. In advanced pre-clinical development, it aims to address respiratory and dermal inflammation
    Longevity pillar
    • Prevention
    • Treatment
    Longevity domain:
    • Longevity immunity
    Longevity target: Aging Driver
    announces the completion of a phase 1b for the treatment of moderately-to-severely active ulcerative colitis. Read more
  • June 1, 2023
    Seal Rock Therapeutics
    Seal Rock therapeutics
    LT 2394
    394 of 880
    Seal Rock Therapeutics is a clinical-stage biotech company dedicated to addressing organ injury, inflammation, and fibrosis caused by various factors. Their focus centers on small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1). With SRT-015, a second-generation ASK1 inhibitor, they are targeting liver diseases through a trimodal therapeutic approach that demonstrates antifibrotic, anti-inflammatory, and anti-apoptotic effects. SRT-015 has successfully completed a phase 1 clinical trial, showcasing promising safety and efficacy. Additionally, Seal Rock Therapeutics has introduced SRT-055, a pioneering dual LRRK2/ASK1 inhibitor, aiming to treat central nervous system disorders such as Parkinson's disease. Their pipeline includes programs for alcoholic hepatitis, NASH, acute liver failure, Parkinson's, and ALS.
    Longevity pillar
    • Treatment
    • Prevention
    Longevity domain:
    • Longevity immunity
    • Discovery platforms
    • Neuropharma
    Longevity target: Aging Disease, Aging Driver
    announces out-licensing agreement with GENFIT. Read more
  • May 31, 2023
    Humacyte
    Humacyte Inc.
    LT 2205
    205 of 880
    Humacyte is at the forefront of developing and producing universally implantable bioengineered human tissues. Their Humacyte Human Acellular Vessel (HAV) is an innovative regenerative vascular conduit undergoing clinical trials for various vascular applications such as trauma repair, hemodialysis access, and peripheral arterial disease. Beyond this, Humacyte envisions their platform technology as having the potential to address complex organ diseases, offering solutions like bioengineered replacement tissues and organs for procedures like coronary artery bypass grafts, pediatric heart surgery, and Type 1 diabetes treatment.
    Longevity pillar
    • Renewal
    • Treatment
    Longevity domain:
    • Regeneration
    Longevity target: Aging Disease
    grows human blood vessels and sends them to wounded Ukraine soldiers. Read more
  • May 30, 2023
    Athersys
    Athersys (NAS: ATHX)
    LT 2048
    48 of 880
    Athersys is a leading biotechnology company specializing in the realm of regenerative medicine. Their unwavering dedication lies in creating therapeutic solutions that surpass current standards of safety and effectiveness, outperforming both existing care norms and contemporaneous developmental products. Central to Athersys' portfolio is MultiStem®, a revolutionary "off-the-shelf" stem cell therapy platform harnessed from adult sources. This innovation is tailored for an array of disease indications within the neurological, inflammatory & immune, and cardiovascular realms, as well as addressing crucial care gaps where current standards of treatment fall short.
    Longevity pillar
    • Treatment
    • Renewal
    Longevity domain:
    • Regeneration
    Longevity target: Aging Driver, Aging Disease
    files to sell 5.685mn shares of common stock for holders. Read more
  • May 30, 2023
    Heartseed
    Heartseed
    LT 2202
    202 of 880
    Heartseed has established a mission focused on "facilitating heart disease treatment through regenerative medicine." Their efforts are dedicated to achieving the earliest feasible application of myocardial regenerative medicine. The organization is actively developing a treatment approach for heart failure, involving the creation of heart cells from induced pluripotent stem cells (iPS cells) and their subsequent transplantation into heart tissue. With substantial backing from numerous entities including companies, academic institutions, and the Japanese government, clinical trials for their flagship candidate, HS-001, are poised to commence shortly. Additionally, Heartseed is engaged in research endeavors aimed at making myocardial regenerative medicine a widespread practice, including investigations into advanced pipelines and streamlined iPS cell production methods.
    Longevity pillar
    • Renewal
    • Treatment
    Longevity domain:
    • Regeneration
    Longevity target: Aging Disease
    bags $14mn Series D. Read more